The FDA votes 12 no to 2 yes on the risk/benefit of Depomed's (DEPO) Gabapentin in treating...

|About: Depomed Inc. (DEPO)|By:, SA News Editor

The FDA votes 12 no to 2 yes on the risk/benefit of Depomed's (DEPO) Gabapentin in treating moderate to severe vasomotor symtoms due to menopause, 13 no and 1 yes on its efficacy. Shares remain halted.